Overview

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

Status:
Terminated
Trial end date:
2012-09-08
Target enrollment:
Participant gender:
Summary
Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease
Phase:
Phase 2
Details
Lead Sponsor:
Amicus Therapeutics